Cargando…
Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) has remained a vexing and poorly managed autoimmune component of Graves’ disease where the tissues surrounding the eye and in the upper face become inflamed and undergo remodeling. This leads to substantial facial disfigurement while in its most severe forms,...
Autor principal: | Smith, Terry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774640/ https://www.ncbi.nlm.nih.gov/pubmed/33391187 http://dx.doi.org/10.3389/fendo.2020.610337 |
Ejemplares similares
-
Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy
por: Adetunji, Modupe O., et al.
Publicado: (2022) -
Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy
por: Smith, Terry J., et al.
Publicado: (2017) -
Treating Thyroid Associated Ophthalmopathy in Pediatric Patients
por: Dong, Tianyu, et al.
Publicado: (2022) -
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021) -
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy
por: Fallahi, Poupak, et al.
Publicado: (2021)